INTS: Intensity Tx Net earnings per share (EPS TTM)

Intensity Therapeutics, Inc. (INTS) - corporate logo

The TTM net income per share distribution for Intensity Therapeutics (INTS) visualizes a monetization strategy centered on intratumoral drugs against metastases. The current value is -4.36, highlighting a reliance on venture capital infusions in the absence of stable cash flow. A team of leading oncologists, attracted by the innovative treatment approach, is spearheading the development. This indicator smooths the time lags between corporate news and the market price.

INTS Intensity Therapeutics Net earnings per share for the last 12 months (02/21/2024 - 11/12/2026)

Summary analytical data breakdowns for Intensity Therapeutics Inc (INTS)

- share price and expert price forecast:
Stock Quotes Intensity Tx|INTS - Fair Value Consensus
- market capitalization information:
Market Capitalization Intensity Therapeutics, Inc.|INTS - Company Buyout Price
- business book valuation details:
Net Assets per Single Share Intensity Therapeutics|INTS - Company Net Assets|Market Value to Book Value Ratio intensitytherapeutics.com|INTS - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Intensity Therapeutics|INTS - Long-Term Debt to Capital|Short-Term Debt to Equity Intensity Tx|INTS - Company Aggregate Debt|Debt to Book Capitalization Ratio Intensity Therapeutics, Inc.|INTS - Long-Term Debt|Company Current Liabilities Intensity Therapeutics|Quick Liquidity Indicator intensitytherapeutics.com
- earnings and multiples data:
INTS - Profit After Payment of Taxes|Projected Future Earnings Intensity Therapeutics|INTS - Company Value to Net Income|Forward P/E Multiple Intensity Tx|INTS - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Intensity Therapeutics, Inc.|INTS - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Intensity Therapeutics|INTS - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months intensitytherapeutics.com|INTS - Earnings per share trend in current year|Expected earnings per share growth for next year Intensity Therapeutics
Fundamental valuation:INTS - intensitytherapeutics.com
Flagship merchandise of Intensity Tx

This indicator is calculated by dividing total annual net income by the total number of shares outstanding. The metric reflects the actual efficiency of profit generation per share, neutralizing the impact of issuance. For Intensity Therapeutics (INTS), this calculation highlights the capital's dependence on the success of a single oncology drug. Binary clinical trial risks make profit dynamics extremely volatile. By analyzing this 12-month net income per share chart, an investor assesses the degree of business scalability.

Main competitors

IBRX: Net earnings per share for the last 12 months|Earnings per share for the trailing year IMCR (immunocore.com)|JANX: Net earnings per share (EPS TTM)|RCUS - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Zymeworks Corp|Net earnings per share for the last 12 months Tango Therapeutics Corp (TNGX)|Earnings per share for the last twelve months Iovance Biotherapeutics (IOVA)|Net earnings per share for the last 12 months immatics.com IMTX|Xencor - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Compass Therapeutics Inc CMPX|REPL - Earnings per share for the last twelve months|LYEL (Lyell Pharma) - Earnings per share for the last 12 months|Innate Pharma S.A. (IPHA) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Pyxis Oncology (PYXS)|Net earnings per share for the last 12 months CGEN|IOBT - Net earnings per share for the trailing year|Net earnings per share for the last 12 months STRO (Sutro Bio)|Earnings per share for the last four quarters INKT|Net earnings per share (EPS TTM) HOWL (Werewolf Therapeutics, Inc.)|Earnings per share for the trailing year IMMX|ALX Oncology Holdings - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months cuebiopharma.com|pdsbiotech.com (PDSB) - Earnings per share for the last twelve months|Sonnet BioTherapeutics Holdings - Earnings per share for the trailing year|MAIA (MAIA Biotechnology) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) liminatuspharma.com|Earnings per share for the last twelve months LAVA Therapeutics N.V. (LVTX)|NXTC: Earnings per one share for the last 12 months|Leap Therapeutics - Net earnings per share for the last 12 months|Sensei Biotherapeutics Inc (SNSE) - Net earnings per one share for the last twelve months|Theriva Biologics, Inc. - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Gritstone bio, Inc. GRTS|Kineta (KA) - Earnings per share for the last twelve months|Earnings per share for the last 12 months NEXI|Net earnings per share for the last 12 months TSBX|VCNX (Vaccinex Inc) - Earnings per share for the last four quarters|Net earnings per share (EPS TTM) HARP